137 related articles for article (PubMed ID: 36441875)
1. The impact of CD56 expression in smoldering myeloma patients on early progression.
Notarfranchi L; Segreto R; Vescovini R; Dalla Palma AB; Marchica V; Burroughs-Garcia J; Toscani D; Todaro G; Raimondi V; Iannozzi NT; Bonomini S; Sammarelli G; Craviotto L; Pedrazzoni M; Storti P; Giuliani N
Hematol Oncol; 2023 Aug; 41(3):587-589. PubMed ID: 36441875
[No Abstract] [Full Text] [Related]
2. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
3. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Am J Hematol; 2021 Mar; 96(3):E63-E65. PubMed ID: 33264449
[No Abstract] [Full Text] [Related]
4. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Kazandjian D; Hill E; Dew A; Morrison C; Roswarski J; Korde N; Emanuel M; Petrosyan A; Bhutani M; Calvo KR; Dulau-Florea A; Kwok M; Lee MJ; Lee S; Lindenberg L; Mailankody S; Manasanch E; Maric I; Mena E; Patel N; Tageja N; Trepel JB; Turkbey B; Wang HW; Wang W; Yuan C; Zhang Y; Braylan R; Choyke P; Stetler-Stevenson M; Steinberg SM; Figg WD; Roschewski M; Landgren O
JAMA Oncol; 2021 Nov; 7(11):1678-1685. PubMed ID: 34529025
[TBL] [Abstract][Full Text] [Related]
5. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
6. Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828-838.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929433
[No Abstract] [Full Text] [Related]
7. Population screening for smoldering multiple myeloma reveals high prevalence.
Nat Med; 2023 Feb; 29(2):313-314. PubMed ID: 36755165
[No Abstract] [Full Text] [Related]
8. Genomic patterns of progression in smoldering multiple myeloma.
Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
[No Abstract] [Full Text] [Related]
10. Smoldering Myeloma Treatment: Who, What, and When.
Mejia Saldarriaga M; Rossi A
Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
[TBL] [Abstract][Full Text] [Related]
11. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
Kunacheewa C; Manasanch EE
Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
[TBL] [Abstract][Full Text] [Related]
12. Smoldering Myeloma and the Art of War.
Lonial S; Dhodapkar MV; Rajkumar SV
J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
[No Abstract] [Full Text] [Related]
13. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
14. Regression of smoldering myeloma with treatment of Gaucher disease.
Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
[No Abstract] [Full Text] [Related]
15. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
[No Abstract] [Full Text] [Related]
16. Successful treatment of systemic sclerosis coexisting with smoldering myeloma.
Smoleńska Ż; Gogulska Z; Dorniak K; Zdrojewski Z
Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34698468
[No Abstract] [Full Text] [Related]
17. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
Gertz MA; Vaxman I
Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
[No Abstract] [Full Text] [Related]
18. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
19. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
[No Abstract] [Full Text] [Related]
20. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
Sørrig R
Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
